Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?

Nishi Karunasinghe; Yifei Zhu; Dug Yeo Han; Katja Lange; Shuotun Zhu; Alice Wang; Stephanie Ellett; Jonathan Masters; Megan Goudie; Justin W L Keogh; Benji Benjamin; Michael Holmes; Lynnette R Ferguson

doi:10.1186/s12894-016-0164-4

Back

Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?

Journal article

Open access

Peer reviewed

Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?

Nishi Karunasinghe, Yifei Zhu, Dug Yeo Han, Katja Lange, Shuotun Zhu, Alice Wang, Stephanie Ellett, Jonathan Masters, Megan Goudie, Justin W L Keogh, …

BMC Urology, Vol.16, 48

2016

DOI: https://doi.org/10.1186/s12894-016-0164-4

Files and links (2)

pdf

PDF - Published Version (Open Access)659.03 kBDownload View

Published VersionPDF - Published Version (Open Access)CC BY V4.0, Open Access

url

https://doi.org/10.1186/s12894-016-0164-4View

Published Version

Abstract

health related quality of life (HRQoL)

androgen deprivation therapy (ADT)

AKR1C3 rs12529 single nucleotide polymorphism (SNP)

Background: Androgen deprivation therapy (ADT) is an effective palliation treatment in men with advanced prostate cancer (PC). However, ADT has well documented side effects that could alter the patient's health-related quality of life (HRQoL). The current study aims to test whether a genetic stratification could provide better knowledge for optimising ADT options to minimize HRQoL effects. Methods: A cohort of 206 PC survivors (75 treated with and 131 without ADT) was recruited with written consent to collect patient characteristics, clinical data and HRQoL data related to PC management. The primary outcomes were the percentage scores under each HRQoL subscale assessed using the European Organisation for Research and Treatment of Cancer Quality of Life questionnaires (QLQ-C30 and PR25) and the Depression Anxiety Stress Scales developed by the University of Melbourne, Australia. Genotyping of these men was carried out for the aldo-keto reductase family 1, member C3 (AKR1C3) rs12529 single nucleotide polymorphism (SNP). Analysis of HRQoL scores were carried out against ADT duration and in association with the AKR1C3 rs12529 SNP using the generalised linear model. P-values <0 . 05 were considered significant, and were further tested for restriction with Bonferroni correction. Results: Increase in hormone treatment-related effects were recorded with long-term ADT compared to no ADT. The C and G allele frequencies of the AKR1C3rs12529 SNP were 53.4 % and 46.6 % respectively. Hormone treatmentrelated symptoms showed an increase with ADT when associated with the AKR1C3 rs12529 G allele. Meanwhile, decreasing trends on cancer-specific symptoms and increased sexual interest were recorded with no ADT when associated with the AKR1C3 rs12529 G allele and reverse trends with the C allele. As higher incidence of cancerspecific symptoms relate to cancer retention it is possible that associated with the C allele there could be higher incidence of unresolved cancers under no ADT options.

Details

Title: Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
Authors: Nishi Karunasinghe (Author) - University of Auckland, New Zealand
Yifei Zhu (Author) - University of Auckland, New Zealand
Dug Yeo Han (Author) - University of Auckland, New Zealand
Katja Lange (Author) - University of Auckland, New Zealand
Shuotun Zhu (Author) - University of Auckland, New Zealand
Alice Wang (Author) - University of Auckland, New Zealand
Stephanie Ellett (Author) - University of Auckland, New Zealand
Jonathan Masters (Author) - Auckland Hospital, New Zealand
Megan Goudie (Author) - Auckland Hospital, New Zealand
Justin W L Keogh (Author) - University of the Sunshine Coast - Faculty of Science, Health, Education and Engineering
Benji Benjamin (Author) - Auckland Hospital, New Zealand
Michael Holmes (Author) - Waikato Hospital, New Zealand
Lynnette R Ferguson (Author) - University of Auckland, New Zealand
Publication details: BMC Urology, Vol.16, 48; 14
Publisher: BioMed Central Ltd.
Date published: 2016
DOI: 10.1186/s12894-016-0164-4
ISSN: 1471-2490
Copyright note: Copyright © 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Organisation Unit: University of the Sunshine Coast, Queensland
Language: English
Record Identifier: 99451053302621
Output Type: Journal article

Metrics

103 File views/ downloads

806 Record Views

20 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Urology & Nephrology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites